lycorine has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, T; Kang, J; Li, C; Liu, X; Wang, H | 1 |
| Cong, X; He, Y; Hu, M; Liu, M; Peng, S; Qin, M; Xing, Y; Yi, Z | 1 |
2 other study(ies) available for lycorine and Prostatic Neoplasms
| Article | Year |
|---|---|
Construction of Fluorescein Isothiocyanate-Labeled MSNs/PEG/Lycorine/Antibody as Drug Carrier for Targeting Prostate Cancer Cells.
Topics: Amaryllidaceae Alkaloids; Antibodies; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fluorescein; Humans; Isothiocyanates; Male; Nanocomposites; Nanoparticles; Phenanthridines; Prostatic Neoplasms | 2018 |
Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.
Topics: Amaryllidaceae Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Phenanthridines; Prostatic Neoplasms; Signal Transduction; STAT3 Transcription Factor; Transplantation, Heterologous | 2015 |